The official Kornelia Polyak Lab Twitter account. The Polyak Lab @DanaFarber Cancer Institute is dedicated to the molecular analysis of human breast cancer.

Joined March 2022
16 Photos and videos
23 Nov 2024
We are thrilled to see our study about ZBTB7A in basal breast cancer is out in @CellReports . We identified ZBTB7A as an novel interactor and regulator of KDM5 using CRISPR screen, and characterized its functional impact on NFkB pathway. Congrats to all!
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer dlvr.it/TGJSQZ
2
7
27
2,486
24 Oct 2024
🎃Polyak lab is getting ready for the MCO halloween pumpkin decoration contest! Huge shoutout to @MarieAnneGoyet1 and Andriana who made this piece of work based on the lab logo! Science and creativity go hand in hand!
11
812
26 Jun 2024
Thrilled to see our paper on KMT2C/2D in TNBC metastasis is out today in @NatureCellBio. We found loss of KMT2C/2D promotes brain metastasis via KDM6A actviation and MMP3 upregulation. Congrats to our twitterless Marco and all the coauthors! nature.com/articles/s41556-0…

1
8
39
2,527
10 May 2024
Our study characterizing breast cancer brain metastasis is officially out in @PNASNews. We reproted breast cancer-stromal cells interaction induces resistance to HER2-targeting agents via bulky glycoproteins. Congrats to @MarieAnneGoyet1 and @nellage. pnas.org/doi/abs/10.1073/pna…
2
8
47
3,286
23 Apr 2024
We are thrilled to announce that Nelly has been elected as a member of the prestigious American Academy of Arts and Sciences. Congratulations! We're so very proud of you!@nellage @DanaFarber @DanaFarberNews
17
5
78
6,482
We are pleased to share our Phase II T-DM1 Pertuzumab clinical trial paper is online in @jclinicalinvest today. Tumors w/ or w/o HER2 heterogeneity show distinct modes of response and resistance towards anti-HER2 agents. jci.org/articles/view/176454
1
4
21
1,598
31 Jan 2024
We are thrilled to see our IBC clinical trial study is officially out in @BCRJournal. We found the use JAK1/2 inhibitor Ruxolitinib in TN-IBC resulted in decreased pSTAT3 but lack of clinical benefits. Comb with immunotherapy may need to be considered. breast-cancer-research.biome…
1
6
21
2,789
20 Dec 2023
Our resource paper on TNBC omic is officially out in @CellReports. We dissected TNBC heterogeneity with deep multiomic profiling on 34 TNBC cell lines and identified drivers of TNBC classification. Congrats to all! @nellage sciencedirect.com/science/ar…

2
22
77
10,075
24 Nov 2023
Congrats Nelly for receiving the 2023 #AACR Distinguished Lectureship in Breast Cancer Research Award! We take immense pride in this remarkable achievement, and we remain dedicated to our ongoing efforts in the fight against breast cancer.
Dr. Kornelia P_olyak, a @DanaFarber leading basic and translational scientist in #breastcancer research, is the recipient of the 2023 #AACR Distinguished Lectureship in Breast Cancer Research Award, which will be presented at #SABCS23. @LabPolyak @nellage aacr.org/about-the-aacr/news…
14
4
84
17,749
Our preclinical study evaluating the efficacy of BRD4 inhibitor Paclitaxel anti-PD-L1 combination for TNBC is out in @MCT_AACR today. Congrats to all the coauthors! And of course a lot more to be explored in the future. @nellage aacrjournals.org/mct/article…
10
34
3,258